<DOC>
	<DOCNO>NCT00552279</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish central cause cervical cancer . The current phase 3b study design assess immunogenicity safety GlaxoSmithKline Biologicals ' HPV vaccine GSK580299 administer accord alternative dosing schedule compare standard dosing schedule young female subject age 15 - 25 year . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity Safety GlaxoSmithKline Biologicals ' Huma Papillomavirus ( HPV ) Vaccine 580299 Healthy Females 15 - 25 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe and/or parent ( ) /Legally acceptable representative ( ) ( LAR ) comply requirement protocol A female include 15 25 year age time first vaccination . Written inform consent obtain subject prior enrolment . For subject legal age consent , write informed consent must obtain subject 's parents/legally acceptable representative ( LAR ) , write informed assent must obtain subject . Healthy subject establish medical history and/or clinical examination enter study . Subject must nonchildbearing potential , child bear potential , must practice adequate contraception 30 day prior vaccination , negative urine pregnancy test continue precaution 2 month completion vaccination series . Subject 6 lifetime sexual partner prior enrolment . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day 30 day first dose vaccine . Planned administration/administration routine vaccine 8 day first dose study vaccine allow . Enrolment deferred patient outside specify window . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Previous vaccination HPV plan administration HPV vaccine foreseen study protocol study period . previous administration component investigational vaccine Cancer autoimmune disease treatment . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine . Hypersensitivity latex Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede blood sampling . Pregnant breastfeed female . Female plan become pregnant , likely become pregnant ( determined investigator ) planning discontinue contraceptive precaution study period start visit one two month last vaccine dose . Acute chronic clinically significant pulmonary , cardiovascular , hepatic renal function abnormality determine physical examination lab test .</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HPV</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>papillomavirus</keyword>
	<keyword>Human papillomavirus ( HPV ) vaccine</keyword>
</DOC>